Here are three notes:
- The specific IV products are 3,000-milliliter 0.9% sodium chloride irrigation and 1,000-milliliter 5% dextrose plus 0.9% sodium chloride, according to the letter.
- This change applies both to Baxter’s direct customers and its distribution partners, though there may be a one- to two-week delay in product flow through the distribution network. Allocations for children’s hospitals and renal customers remain unchanged, as do other existing allocations for specific groups.
- According to the letter, the decision was based on the progress of remediation efforts at the North Cove facility, reallocation of capacity from other Baxter facilities and the temporary importation of specific products. Baxter also emphasized the ongoing need for conservation strategies to help manage supply levels.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
